window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 2, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

atopic dermatitis

  • Dermatology,Market Access & Commercialization,Medical devices,Partnerships & Funding

    Hyphens Pharma out-licenses Cerapro MED cream for six European markets

    Hyphens Pharma International Limited (Hyphens Pharma), a Singapore-based specialty pharmaceutical [...]

    January 5, 2026
  • Dermatology,Events and Conferences,Immunology,Mental health,Patient Centricity,Pharmaceuticals and therapeutics

    Almirall ImmunoSkin brings experts together to advance treatment of inflammatory skin diseases

    Almirall has hosted the fourth edition of ImmunoSkin, its annual [...]

    November 12, 2025
  • Events and Conferences,Patient Centricity,Pharmaceuticals and therapeutics,Real world evidence,Research & Development

    EADV 2025: Almirall showcases real-world evidence and pipeline progress in dermatology

    Almirall, a global biopharmaceutical company focused on medical dermatology, has [...]

    September 22, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Chronic diseases,Drug Development,Partnerships & Funding

    KBI Biopharma and Infinimmune partner on antibody manufacturing for atopic dermatitis programme

    KBI Biopharma has entered a collaboration with Infinimmune to support [...]

    September 17, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Delivery & Formulation,Drug Development,Precision medicine

    Revolo moves oral formulation of allergy drug into development following preclinical boost

    Revolo Biotherapeutics says it is accelerating plans to bring a [...]

    August 6, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Rare Diseases,Regulatory Affairs

    FDA grants fast track to Nektar’s rezpegaldesleukin for severe alopecia areata

    Nektar Therapeutics has received FDA Fast Track designation for its [...]

    July 29, 2025
  • Clinical Development,Clinical Trials,Patient Centricity

    Phesi CEO warns of looming Phase 3 trial failures as sponsors overlook real-world data and overcrowd sites

    New analysis reveals billions risked on overly complex trials that [...]

    July 10, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ARTCLINE completes enrolment in septic shock trial for ARTICE therapy
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Infectious Diseases, Pharmaceuticals and therapeutics
  • SGD Pharma highlights GLP-1 demand, supply chain pressure and sustainability focus at DCAT Week
    Categories: CDMOs & Manufacturing, Healthcare leadership, Market Access & Commercialization, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top